Drug Trial Radar · NCT06227832
A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Dec 15, 2023
Primary completion
Mar 15, 2024
Study completion Jul 31, 2024
Sponsor
- Lead sponsor
- Kaken PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Jan 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the Effects of KP-001 on Metformin (a substrate of MATE1) and Midazolam (a substrate of CYP3A4) Pharmacokinetics and the Effect of Clarithromycin (potent CYP3A4/P-gp Inhibitor) on KP-001 Pharmacokinetics in Healthy Adult Participants. The study will also evaluate the safety and tolerability of KP-001 with and without a single dose or multiple doses of an interaction drug. The study comprises 3 parts. Participants will stay in the Clinical Unit during the study, depending on which part they assigned to. Participants will remain at the clinical site for a 13 day/12 night in-house stay (Part 1), a 14 day/13 night in house stay (Part 2), or a 11 day/10 night in-house stay (Part 3).
Conditions
- Healthy Adults
Interventions
KP-001Drug
KP-001
MetforminDrug
oral dose of 850 mg Metformin
MidazolamDrug
oral dose of 2 mg Midazolam
ClarithromycinDrug
oral doses of 1000 mg Clarithromycin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic (PK) parameters of metformin in plasma: Area under the concentration-time curve from time 0 extrapolated to infinite time (AUCinf)Time frame: 13 days
- PK parameters of midazolam in plasma: AUCinfTime frame: 14 days
- PK parameters of KP-001 in plasma: AUCinfTime frame: 11 days
- PK parameters of metformin in plasma: Maximum observed concentration (Cmax)Time frame: 13 days
- PK parameters of midazolam in plasma: CmaxTime frame: 14 days
- PK parameters of KP-001 in plasma: CmaxTime frame: 11 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel Early Phase Clinical Unit - Los Angeles
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.